DDI2-NFE2L1-Proteasome System: A New Axis in Ferroptosis Regulation

Study Background and Research Question

Ferroptosis is a distinct, non-apoptotic form of regulated cell death defined by iron-dependent lipid peroxidation and subsequent plasma membrane rupture. It is increasingly recognized as a contributor to the pathology of neurodegenerative diseases and cancer. Central to the cellular defense against ferroptosis is glutathione peroxidase 4 (GPX4), which detoxifies lipid peroxides using glutathione. Inhibition of GPX4, for example by the small molecule RSL3, triggers ferroptosis by overwhelming these antioxidant defenses. However, recent work suggests that proteostasis mechanisms—specifically, the ubiquitin-proteasome system (UPS)—are also crucial in determining cellular sensitivity to ferroptosis. The reference study (Ofoghi et al., 2025) sought to clarify how adaptive remodeling of the UPS, via the transcription factor NFE2L1 and its activating protease DDI2, influences ferroptotic cell death and whether this axis can be targeted pharmacologically (DOI:10.1038/s41418-024-01398-z).

Key Innovation from the Reference Study

The major advance of this work is the elucidation of a feedback mechanism wherein ferroptosis-induced oxidative stress leads to impaired proteasome activity, which, in turn, triggers activation of NFE2L1 via proteolytic cleavage by DDI2. Activated NFE2L1 then upregulates expression of proteasome subunit genes, restoring UPS function and providing protection against ferroptosis. Importantly, the study shows that genetic or pharmacological inhibition of DDI2 prevents NFE2L1 activation, resulting in defective proteasome recovery and increased ferroptotic sensitivity. Notably, the clinical drug Nelfinavir Mesylate, previously characterized as an HIV-1 protease inhibitor, was shown to inhibit DDI2 and thereby sensitize cells to ferroptosis (reference).

Methods and Experimental Design Insights

To dissect the regulatory circuit connecting ferroptosis, NFE2L1, and UPS remodeling, the authors employed a combination of unbiased proteomic profiling, genetic perturbations, and chemical inhibitors. Key approaches included:

• Quantitative mass spectrometry to map global ubiquitylation changes in response to ferroptosis induction (via RSL3).
• Reporter assays and immunoblotting to assess NFE2L1 activation and proteasome subunit gene expression.
• Genetic ablation of DDI2 to evaluate its necessity in NFE2L1 activation during ferroptotic stress.
• Use of Nelfinavir Mesylate to pharmacologically inhibit DDI2 and examine effects on ferroptosis sensitivity.

This multidimensional approach enabled precise attribution of observed phenotypes—such as global hyperubiquitylation, proteasome impairment, and increased cell death—to discrete molecular nodes within the DDI2-NFE2L1-UPS axis.

Core Findings and Why They Matter

The study's main findings can be summarized as follows:

• Ferroptosis impairs proteasome function and increases protein ubiquitylation: RSL3-mediated GPX4 inhibition led to decreased proteasome activity and accumulation of ubiquitylated proteins, indicating proteostasis stress [source_type: paper][source_link: https://doi.org/10.1038/s41418-024-01398-z].
• NFE2L1 is activated as a compensatory response: In this context, NFE2L1 undergoes cleavage by DDI2 and migrates to the nucleus to induce proteasome subunit gene expression, restoring proteasome activity [source_type: paper][source_link: https://doi.org/10.1038/s41418-024-01398-z].
• DDI2 is essential for NFE2L1-driven proteasome recovery: Cells lacking DDI2 cannot activate NFE2L1 in response to ferroptosis, leading to persistent proteasome dysfunction and increased ferroptotic death [source_type: paper][source_link: https://doi.org/10.1038/s41418-024-01398-z].
• Nelfinavir Mesylate sensitizes cells to ferroptosis: By inhibiting DDI2, Nelfinavir Mesylate blocks NFE2L1 activation and proteasome recovery, thereby increasing susceptibility to ferroptosis [source_type: paper][source_link: https://doi.org/10.1038/s41418-024-01398-z].

These findings establish the DDI2-NFE2L1-UPS pathway as a critical determinant of ferroptotic sensitivity and highlight a new potential target for modulating ferroptosis in disease models, with direct implications for cancer therapy where induction of ferroptosis may be desirable.

Protocol Parameters

• Ferroptosis induction (RSL3) | 1–2 μM | in vitro cell models | Standard concentration for robust GPX4 inhibition and ferroptosis induction in mammalian cells | paper [DOI]
• Nelfinavir Mesylate (DDI2 inhibition) | 5–20 μM | in vitro DDI2 inhibition | Effective range for blocking DDI2-mediated NFE2L1 cleavage and increasing ferroptotic cell death | paper [DOI]
• Proteasome activity assay | Fluorogenic substrate, 30 min incubation | Applicability to cell lysates | Allows quantification of UPS function following genetic or pharmacological perturbation | paper [DOI]
• Ubiquitylation profiling | Mass spectrometry-based, site-specific | Proteome-wide analysis | Detects global and site-specific changes in ubiquitylation during ferroptosis | paper [DOI]

Comparison with Existing Internal Articles

Several internal articles have explored the dual roles of Nelfinavir Mesylate in both HIV infection research and emerging cell death pathways. For instance, the article "Nelfinavir Mesylate: Bridging HIV Protease Inhibition and Ferroptosis Modulation" provides a mechanistic synthesis of how Nelfinavir, beyond its established use as an antiretroviral drug for HIV treatment, can modulate the UPS through DDI2 inhibition, thus sensitizing cells to ferroptosis (internal article). Similarly, "Nelfinavir Mesylate at the Nexus of HIV Suppression and Ferroptosis" contextualizes the translational impact of these findings for oncology and neurodegeneration models (internal article). The current reference paper advances these discussions by providing direct evidence for the DDI2-NFE2L1-UPS mechanism using unbiased proteomics and genetic models, substantiating the framework posited by previous reviews.

Limitations and Transferability

The study was conducted using in vitro cell culture models and acute chemical/genetic perturbations. While these approaches robustly demonstrate the mechanistic role of DDI2-NFE2L1 signaling in ferroptosis regulation, the physiological relevance in vivo and across diverse tissue types remains to be fully established. Furthermore, while Nelfinavir Mesylate was effective in sensitizing cells to ferroptosis via DDI2 inhibition in cell-based assays, its selectivity for DDI2 relative to other proteases and its effects in animal models or clinical contexts require further investigation [source_type: workflow_recommendation]. Researchers should also consider cell-type-specific responses and potential off-target effects when translating these findings.

Why this cross-domain matters, maturity, and limitations

The finding that Nelfinavir Mesylate—a clinically approved HIV-1 protease inhibitor—can modulate ferroptosis sensitivity via DDI2 inhibition exemplifies the value of drug repurposing and cross-domain research. This cross-talk between antiviral drug mechanisms and regulated cell death pathways opens new avenues for translational applications in cancer and neurodegeneration research. However, most evidence to date is preclinical, and direct clinical utility for ferroptosis modulation, outside of HIV infection research, awaits further validation [source_type: workflow_recommendation].

Outlook

Future studies will be required to determine the therapeutic window and selectivity of DDI2-targeted interventions for ferroptosis sensitization in vivo. The mechanistic framework established here paves the way for rational design of combination therapies that exploit vulnerabilities in the UPS under ferroptotic stress, with potential to enhance the efficacy of existing cancer treatments (reference).

Research Support Resources

To enable similar workflows, researchers can source Nelfinavir Mesylate (SKU A3653), a well-characterized HIV-1 protease inhibitor with proven utility in both HIV protease inhibition assays and ferroptosis research. For detailed compound specifications, refer to APExBIO's product page. Careful optimization of assay conditions and controls is recommended to ensure specificity and reproducibility in DDI2-NFE2L1-UPS investigations.